|
|
|
|
|
| Takahashi,Hiroshi; Ikeda,Kazuhiko; Ogawa,Kazuei; Saito,Syunnichi; Ngoma,Alain M; Mashimo,Yumiko; Ueda,Koki; Furukawa,Miki; Shichishima-Nakamura,Akiko; Ohkawara,Hiroshi; Nollet,Kenneth E; Ohto,Hitoshi; Takeishi,Yasuchika. |
| BACKGROUND: CD4+CD25highFOXP3+ regulatory T (Treg) cells, which include thymus-derived and peripherally induced cells, play a central role in immune regulation, and are therefore crucial to prevent graft-versus-host disease (GVHD). The increasing use of allogeneic hematopoietic stem cell transplantation (allo-HSCT) for elderly patients with thymus regression, and our case of allo-HSCT shortly after total thymectomy, raised questions about the activity of thymus-derived Treg cells and peripherally induced Treg cells, which are otherwise indistinguishable. RESULTS: We found that despite pre-transplant thymectomy or older age, both naïve and effector Treg cells, as well as naïve and effector conventional T cells, proliferated in allo-HSCT recipients. Higher... |
| Tipo: Journal article |
Palavras-chave: Regulatory T cells; Allogeneic hematopoietic stem cell transplantation; Thymus; Graft-versus-host disease. |
| Ano: 2015 |
URL: http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0716-97602015000100041 |
| |
|
| |
|
| |
|
|
| Resende,C.B.; Rezende,B.M.; Bernardes,P.T.T.; Teixeira,G.M.; Teixeira,M.M.; Pinho,V.; Bittencourt,H.. |
| Acute graft-versus-host disease (aGVHD) and cytomegalovirus reactivation are important complications after allogeneic stem cell transplantation (alloHSCT). Here, we evaluated the impact of treatment with alemtuzumab on the occurrence of aGVHD, cytomegalovirus reactivation and survival after alloHSCT. This was a prospective cohort study conducted at the allo-HSCT unit of Hospital das Clínicas, Universidade Federal de Minas Gerais, Brazil, from January 2009 to December 2011. Fifty-seven patients who underwent alloHSCT were included. Forty-five (79%) patients had a malignant disease. Alemtuzumab was administered before the conditioning regimen at a dose of 1 mg/kg in children and 30 mg/day for 2 days in adults or children weighing more than 40 kg (a total... |
| Tipo: Info:eu-repo/semantics/article |
Palavras-chave: Hematopoietic stem cell transplantation; Alemtuzumab; Graft-versus-host disease; Cytomegalovirus. |
| Ano: 2017 |
URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2017000200705 |
| |
|
|
| Nogueira,M.C.; Azevedo,A.M.; Pereira,S.C.M.; Ferreira,J.L.; Lerner,D.; Lobo,A.M.G.; Tavares,R.C.B.S.; Tabak,D.G.; Lorenzi,N.; Renault,I.Z.; Bouzas,L.F.S.. |
| Allogeneic stem cell transplantation has been increasingly performed for a variety of hematologic diseases. Clinically significant acute graft-versus-host disease (GVHD) occurs in 9 to 50% of patients who receive allogeneic grafts, resulting in high morbidity and mortality. There is no standard therapy for patients with acute GVHD who do not respond to steroids. Studies have shown a possible benefit of anti-TNF-a (infliximab)for the treatment of acute GVHD. We report here on the outcomes of 10 recipients of related or unrelated stem cell transplants who received 10 mg/kg infliximab, iv, once weekly for a median of 3.5 doses (range: 1-6) for the treatment of severe acute GVHD and who were not responsive to standard therapy. All patients had acute GVHD... |
| Tipo: Info:eu-repo/semantics/article |
Palavras-chave: Infliximab; Graft-versus-host disease; Hematopoietic stem cell transplantation. |
| Ano: 2007 |
URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2007001200005 |
| |
|
|
|
